Effects of Atropine Treatment on Choroidal Thickness in Myopic Children

Overview

Journal Invest Ophthalmol Vis Sci

Specialty Ophthalmology

Date 2020 Dec 15

PMID 33320168

Citations 19

Authors

Luyao Ye

Ya Shi

Yao Yin

Shanshan Li

Jiangnan He

Jianfeng Zhu

Xun Xu

Affiliations

Soon will be listed here.

Abstract

Purpose: To examine the changes in choroidal thickness (ChT) after 6 months of 1% or 0.01% atropine treatment and the independent factors associated with eye elongation.

Methods: A total of 207 myopic children aged 6 to 12 years were recruited and randomly assigned to groups A and B in a ratio of 1:1. Participants in group A received 1% atropine once a day for 1 week, and then once a week for 23 weeks. Participants in group B received 0.01% atropine once a day for 6 months. ChT and internal axial length (IAL) were measured at baseline, 1 week, 3 months, and 6 months.

Results: In group A, the ChT significantly increased after a 1-week loading dose of 1% atropine (26 ± 14 µm; P < 0.001) and the magnitude of increase stabilized throughout the following weekly treatment. The internal axial length did not significantly change at the 6-month visit (-0.01 ± 0.11 mm; P = 0.74). In contrast, a decreased ChT (-5 ± 17 µm; P < 0.001) and pronounced eye elongation (0.19 ± 0.12 mm; P < 0.001) were observed in group B after 6 months. Multivariable regression analysis showed that less increase in ChT at the 1-week visit (P = 0.03), younger age (P < 0.001), and presence of peripapillary atrophy (P = 0.001) were significantly associated with greater internal axial length increase over 6 months in group A.

Conclusions: One percent atropine could increase the ChT, whereas 0.01% atropine caused a decrease in ChT after 6 months of treatment. For participants receiving 1% atropine, the short-term increase in ChT was negatively associated with long-term eye elongation. Younger age and the presence of peripapillary atrophy were found to be risk factors for greater eye elongation.

Citing Articles

Short-term effectiveness and safety of photobiomodulation on low-to-moderate myopia.

Ren J, Xu J, Liu Y, Gu X, Wang Y Lasers Med Sci. 2025; 40(1):95.

PMID: 39954097 DOI: 10.1007/s10103-024-04119-7.

Fundus vascular arcades angle reflects choroidal thickness in highly myopic children and adolescents.

Gong W, Zhang B, Zhou D, Ling S, Yang J, Chen J Eye (Lond). 2025; .

PMID: 39827236 DOI: 10.1038/s41433-025-03604-9.

Choroidal thickness under pilocarpine versus cyclopentolate.

Bikbov M, Kazakbaeva G, Panda-Jonas S, Mustafina G, Jonas J Sci Rep. 2025; 15(1):2221.

PMID: 39824947 PMC: 11742028. DOI: 10.1038/s41598-025-85712-w.

Efficacy of defocus incorporated multiple segments (DIMS) lenses and low-dose atropine on retarding myopic shift among premyopic preschoolers: Protocol for a prospective, multicenter, randomized controlled trial.

Yang H, Tsai D, Yang Y, Wang C, Lee C, Huang P PLoS One. 2024; 19(12):e0312935.

PMID: 39739826 PMC: 11687691. DOI: 10.1371/journal.pone.0312935.

Effects of computer-generated patterns with different temporal and spatial frequencies on choroidal thickness, retinal dopamine and candidate genes in chickens wearing lenses.

Liu H, Schaeffel F, Feldkaemper M Front Med (Lausanne). 2024; 11:1469275.

PMID: 39720655 PMC: 11666368. DOI: 10.3389/fmed.2024.1469275.

References

Nickla D, Wilken E, Lytle G, Yom S, Mertz J . Inhibiting the transient choroidal thickening response using the nitric oxide synthase inhibitor l-NAME prevents the ameliorative effects of visual experience on ocular growth in two different visual paradigms. Exp Eye Res. 2006; 83(2):456-64. DOI: 10.1016/j.exer.2006.01.029. View

Yam J, Jiang Y, Tang S, Law A, Chan J, Wong E . Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. Ophthalmology. 2018; 126(1):113-124. DOI: 10.1016/j.ophtha.2018.05.029. View

Rada J, Huang Y, Rada K . Identification of choroidal ovotransferrin as a potential ocular growth regulator. Curr Eye Res. 2001; 22(2):121-32. DOI: 10.1076/ceyr.22.2.121.5525. View

Read S, Collins M, Sander B . Human optical axial length and defocus. Invest Ophthalmol Vis Sci. 2010; 51(12):6262-9. DOI: 10.1167/iovs.10-5457. View

Simon P, Feldkaemper M, Bitzer M, Ohngemach S, Schaeffel F . Early transcriptional changes of retinal and choroidal TGFbeta-2, RALDH-2, and ZENK following imposed positive and negative defocus in chickens. Mol Vis. 2004; 10:588-97. View

Fang Y, Yokoi T, Nagaoka N, Shinohara K, Onishi Y, Ishida T . Progression of Myopic Maculopathy during 18-Year Follow-up. Ophthalmology. 2018; 125(6):863-877. DOI: 10.1016/j.ophtha.2017.12.005. View

Gupta P, Thakku S, Saw S, Tan M, Lim E, Tan M . Characterization of Choroidal Morphologic and Vascular Features in Young Men With High Myopia Using Spectral-Domain Optical Coherence Tomography. Am J Ophthalmol. 2017; 177:27-33. DOI: 10.1016/j.ajo.2017.02.001. View

Repka M, Cotter S, Beck R, Kraker R, Birch E, Everett D . A randomized trial of atropine regimens for treatment of moderate amblyopia in children. Ophthalmology. 2004; 111(11):2076-85. DOI: 10.1016/j.ophtha.2004.04.032. View

Dolgin E . The myopia boom. Nature. 2015; 519(7543):276-8. DOI: 10.1038/519276a. View

10.

Zhu Q, Tang Y, Guo L, Tighe S, Zhou Y, Zhang X . Efficacy and Safety of 1% Atropine on Retardation of Moderate Myopia Progression in Chinese School Children. Int J Med Sci. 2020; 17(2):176-181. PMC: 6990884. DOI: 10.7150/ijms.39365. View

11.

Nickla D, Wallman J . The multifunctional choroid. Prog Retin Eye Res. 2010; 29(2):144-68. PMC: 2913695. DOI: 10.1016/j.preteyeres.2009.12.002. View

12.

Woodman-Pieterse E, Read S, Collins M, Alonso-Caneiro D . Regional Changes in Choroidal Thickness Associated With Accommodation. Invest Ophthalmol Vis Sci. 2015; 56(11):6414-22. DOI: 10.1167/iovs.15-17102. View

13.

Gong Q, Janowski M, Luo M, Wei H, Chen B, Yang G . Efficacy and Adverse Effects of Atropine in Childhood Myopia: A Meta-analysis. JAMA Ophthalmol. 2017; 135(6):624-630. PMC: 5710262. DOI: 10.1001/jamaophthalmol.2017.1091. View

14.

Nickla D, Totonelly K, Dhillon B . Dopaminergic agonists that result in ocular growth inhibition also elicit transient increases in choroidal thickness in chicks. Exp Eye Res. 2010; 91(5):715-20. PMC: 2962673. DOI: 10.1016/j.exer.2010.08.021. View

15.

Yi S, Huang Y, Yu S, Chen X, Yi H, Zeng X . Therapeutic effect of atropine 1% in children with low myopia. J AAPOS. 2015; 19(5):426-9. DOI: 10.1016/j.jaapos.2015.04.006. View

16.

Yan Y, Wang Y, Yang Y, Xu L, Xu J, Wang Q . Ten-Year Progression of Myopic Maculopathy: The Beijing Eye Study 2001-2011. Ophthalmology. 2018; 125(8):1253-1263. DOI: 10.1016/j.ophtha.2018.01.035. View

17.

Parssinen O, Kauppinen M . Risk factors for high myopia: a 22-year follow-up study from childhood to adulthood. Acta Ophthalmol. 2018; 97(5):510-518. DOI: 10.1111/aos.13964. View

18.

Wu P, Yang Y, Fang P . The long-term results of using low-concentration atropine eye drops for controlling myopia progression in schoolchildren. J Ocul Pharmacol Ther. 2011; 27(5):461-6. DOI: 10.1089/jop.2011.0027. View

19.

Hung L, Wallman J, Smith 3rd E . Vision-dependent changes in the choroidal thickness of macaque monkeys. Invest Ophthalmol Vis Sci. 2000; 41(6):1259-69. View

20.

Wu H, Chen W, Zhao F, Zhou Q, Reinach P, Deng L . Scleral hypoxia is a target for myopia control. Proc Natl Acad Sci U S A. 2018; 115(30):E7091-E7100. PMC: 6064999. DOI: 10.1073/pnas.1721443115. View